Clvs | search
Click here to view Clvs news from 60+ newspapers.
Bookmark or Share- Clovis' (CLVS) Rubraca Gets FDA Approval for Prostate CancerClovis' (CLVS) PARP inhibitor, Rubraca, receives approval from the FDA as monotherapy to treat BRCA-mutant metastatic castration-resistant prostate cancer.
- Clovis (CLVS) Focuses on Rubraca Growth Amid Rising CompetitionClovis Oncology's (CLVS) sole marketed drug Rubraca has been approved for multiple cancer indications. Yet, the drug's sales remain tepid on account of competition from PARP inhibitors.
- Clovis (CLVS) Up 24% on Upbeat Data From Ovarian Cancer StudyClovis Oncology's (CLVS) stock price rises after it reports favorable data from a late-stage study on Rubraca as the first-line maintenance treatment of ovarian cancer.
- Fresno trucking company manager sentenced in $1.6M fraud schemeA California man was sentenced to two years and nine months in federal prison for embezzling nearly $1.6 million from the Fresno-based trucking company where he worked for 15 years. The post ...
- Clovis (CLVS) Files for Bankruptcy Amid Lack of Financial AidClovis Oncology, Inc. CLVS announced that the company and some of its subsidiaries initiated voluntary prearranged Chapter 11 proceedings in the U.S. Bankruptcy Court for the Southern District of ...
More
